Deloitte January 25, 2024
Investments in end-to-end digitalization can overhaul the industry’s supply chain processes while keeping patients’ best interests at the fore and the competition at bay.
Executive summary
Pandemic-induced disruptions. A need for greater flexibility and agility (especially in delivering advanced therapies to patients). Fear of falling behind competitors investing in digitalization. These are just a few of the reasons biopharma companies might prioritize the digitalization of supply chain processes, from developing, manufacturing, and delivering a product to providing postdelivery support. In addition to benefiting from reduced costs and automated processes, biopharma companies with digitalized supply chains tend to be better equipped to meet evolving regulations, ensure patient safety, and realize sustainability goals.
The Deloitte Center for Health Solutions...
Today's Sponsors
Today's Sponsor